Dr. Rae is a research scientist with principal expertise in the areas of drug metabolism, pharmacogenetics, pharmacogenomics, translational oncology, biomarker identification and characterization, and estrogen receptor signaling and particularly as these may apply to the prediction of breast cancer treatment response. He holds dual faculty appointments at the University of Michigan in the Department of Internal Medicine and the Department of Pharmacology. He’s involved in a number of large team science studies and has been a member of the NCI’s National Clinical Trials Network (NCTN) SWOG cooperative group where he serves as the Executive Officer of Translational Medicine, overseeing the operations of the SWOG’s Biospecimen Bank, and works extensively with the Breast Committee fostering correlative science and translational studies. He is on the Board of Directors of the HOPE Foundation for Cancer Research and provides scientific input for funding of research grants, fellowships, training events, physician education, and patient advocacy. In addition, he serves on the NCTN Biospecimen Banks Group Banking Committee and the NCTN Core Correlative Sciences Review Committee. As a member of the Translational Breast Cancer Research Consortium (TBCRC), he co-Chairs the Endocrine Resistance Working group and participates in the development of research clinical trials and their associated correlative translational studies. He has published extensively in the areas of pharmacogenetics, drug metabolism, and breast cancer. His laboratory research is a testament to the fact that he has made important contributions to a highly clinically-relevant field, both as a significant participate in team-science based projects, and focused, hypothesis-driven research projects.